Xerostomia Therapeutics Market Analysis with Top Manufactures and Business Opportunities

Xerostomia Therapeutics Market report examines the short-and medium-term economic and profitability outlook for Xerostomia Therapeutics industry. Xerostomia Therapeutics Market Report is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). Few of the major are Acacia Pharma Group PLC, Colgate-Palmolive, Church & Dwight Co. Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin, OraCoat, Parnell Pharmaceuticals Inc., Pendopharm, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Synedgen Inc.

The Global Xerostomia Therapeutics Market accounted for USD 8.78 billion in 2017 and is projected to grow at a CAGR of 5.9% during the forecast period of 2019 to 2026.

Get Exclusive Sample Report: @

Xerostomia is a disease leading to oral dryness and are not easily diagnosed. Dryness of mouth is associated with the altered salivary gland functionality and other etiologies causing oral issues. Xerostomia caused due to the absence of saliva flow, and this is due to shrinkage of salivary gland. The xerostomia therapeutics helps to treat these symptoms associated with the dry mouth. The dry mouth symptoms impacts the life style quality of the patient and causes difficulty in the swallowing, chewing and speaking which can lead to the thick oral mucus, sleep disturbance and bad breathing.

Market Drivers:

Rising geriatric population has increased the demand for these therapeutics as the elderly population have more symptoms of dry mouth

Increase in use of prescription medications

Market Restraints:

High cost of xerostomia therapeutics is acting as a major restraint for the market

Lack of awareness of xerostomia in the developing and underdeveloped economies

Global Xerostomia Therapeutics Market, By Type (Salivary Stimulants, Salivary Substitutes, Dentifrices), Prescription based (OTC, Prescribed), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Primary Respondents:

  • Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Access Detailed TOC@

Global Xerostomia Therapeutics Market Size, Status and Forecast 2019 – 2026

1 Market Overview

2 Manufacturers Profiles

3 Global Xerostomia Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer

4 Global Xerostomia Therapeutics Market Analysis by Regions

5 North America Xerostomia Therapeutics by Countries

6 Europe Xerostomia Therapeutics by Countries

7 Asia-Pacific Patient Temperatures Monitoring by Countries

8 South America Xerostomia Therapeutics by Countries

9 Middle East and Africa Xerostomia Therapeutics by Countries

10 Global Xerostomia Therapeutics Market Segment by Type

11 Global Xerostomia Therapeutics Market Segment by Application

12 Xerostomia Therapeutics Market Forecast

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendixes

The Report Highlights

Historic and forecasted Xerostomia Therapeutics market size in terms of revenues & unit sales, average selling price, growth rates, and company market shares.

Highlights and compares key application/product categories for growth trends and revenue forecast.

Xerostomia Therapeutics Market size, revenue and unit sales according to each region

Cross category comparison – Growth and revenue comparison for product categories, historic and forecast through 2026.

Xerostomia Therapeutics Market share of top key players

Current trends and recent Developments

Buy Report@

Key Developments in the Market:

In October 2018, Synedgen Incand the subsidiary Prisyna, announced the launch of Moisyn for the treatment of xerostomia dry mouth.

May 2018, Synedgen Inc. and the subsidiary Prisyna , received 510(k) clearance from the US Food and Drug Administration (FDA) to market its family of Moisyn products designed to treat xerostomia.  The clearance of the drug from FDA will help the company to provide the Moisyn products to the patients for the treatment and can alleviate the dry mouth symptoms.

Scope of the Xerostomia Therapeutics Market Report

Xerostomia Therapeutics Market (Actual Period: 2017-2018, Forecast Period: 2019-2026)

Xerostomia Therapeutics Market – Size, Growth, Forecast

Analysis By Type:

Regional Analysis – Actual Period: 2017-2018, Forecast Period: 2019-2026

Xerostomia Therapeutics Market – Size, Growth, Forecast

Xerostomia Therapeutics Market Analysis by Type

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market


Data Bridge Market Research

Tel: +1-888-387-2818



Show More